Wall Street Pulls Back on Novo Nordisk and Jefferies While Talkspace Heads for Exit

Four names are drawing analyst attention this week, with TD Cowen stepping back from Novo Nordisk A/S (NYSE:NVO), Truist trimming its target on Korn Ferry (NYSE:KFY), Morgan Stanley adjusting expectations for Jefferies Financial Group Inc. (NYSE:JEF), and KeyBanc effectively closing the book on Talkspace Inc. (NASDAQ:TALK) following its acquisition announcement. The moves reflect a mix of pipeline disappointment, valuation compression, and deal-driven resolution.

Ticker Company Name Firm Old → New Rating New Price Target Implied Upside vs. Current Price One-Line Takeaway NVO Novo Nordisk A/S TD Cowen Buy → Hold $42 ~6% above $39.78 CagriSema disappointment and pricing headwinds cloud the growth story KFY Korn Ferry Truist Buy (target cut) $75 ~20% above $62.63 Target reduced on lower industry multiples; executive search demand remains resilient JEF Jefferies Financial Group Morgan Stanley Overweight → Equal Weight $49 ~28% above $38.42 Pre-earnings caution; advisory softness expected despite solid underwriting TALK Talkspace KeyBanc Buy → Sector Weight N/A Deal price $5.25 vs. $5.12 Acquisition by UHS at $5.25/share removes upside and downside risk alike The Analysts’ Cases

Novo Nordisk: TD Cowen downgraded Novo Nordisk to Hold from Buy and cut its price target to $42 from $45. The rationale centers on a cluster of concerns that have been building for weeks: ongoing questions around the Wegovy pill, underwhelming CagriSema clinical data, lagging Ozempic prescriptions, and additional caution flagged at a recent healthcare conference. The CagriSema results were the sharpest blow — the drug delivered 23% average body weight reduction in an 84-week trial, falling short of Eli Lilly’s tirzepatide at 25.5% and failing to prove non-inferiority. Goldman Sachs had already moved to Neutral in early March with a $41 target, and Deutsche Bank downgraded to Hold in late February as well. TD Cowen’s action adds to a growing chorus of caution.

Korn Ferry: Truist kept its Buy rating on Korn Ferry but cut the price target to $75 from $88, citing lower industry multiples. The underlying business is holding up: executive search demand grew 11% on a constant-currency basis, and the segment remains more resilient than other human capital management areas. The target reduction is a valuation recalibration rather than a fundamental concern.

Jefferies Financial Group: Morgan Stanley lowered Jefferies from Overweight to Equal Weight, with a price target of $49 implying approximately 28% upside potential from current prices. The downgrade was driven by credit concerns. The move followed a period of generally positive, high-performing sentiment for the stock, with the downgrade reflecting a more cautious stance on the company’s valuation in the current market.

Talkspace: KeyBanc downgraded Talkspace to Sector Weight from Buy following the announcement that Universal Health Services agreed to acquire the company for $5.25 per share in cash. With the deal price set, the rating change is mechanical — there is no longer a meaningful investment thesis to maintain beyond the spread between the current price and the acquisition price. KeyBanc noted the deal reduces volatility risk for a small-cap name.

Company Snapshot & Recent Performance

Novo Nordisk’s stock has been under sustained pressure. Shares are trading at $39.78, down 21.82% year-to-date and 53.14% over the past year. The 52-week high was $80.53, putting the stock’s current level less than $4 above its 52-week low of $35.85. Despite the pressure on the stock, the underlying business delivered: Q4 2025 revenue came in at $45.32 billion, above the $41.57 billion estimate, with obesity care sales up 31% to DKK 82.3 billion. The problem is forward-looking — management guided for adjusted sales growth of -5% to -13% at constant exchange rates in 2026 due to pricing pressures and competition.

Korn Ferry reported a strong Q3 FY2026, with revenue of $725.04 million, up 7.2% year-over-year and above the $695.1 million estimate. Adjusted diluted EPS of $1.28 beat the $1.24 estimate. The stock trades at $62.63, down 5.13% year-to-date. The consensus analyst price target sits at $79, suggesting the stock is broadly viewed as undervalued at current levels even after Truist’s cut.

Jefferies has been one of the harder-hit financial names in 2026. The stock sits at $38.16, down 37.95% year-to-date. The firm’s most recent quarter (Q1 FY2026, reported January 7, 2026) showed EPS of $0.85, missing the $0.93 estimate by 8.6%. However, the full-year FY2025 picture was more constructive, with investment banking net revenues up 20% to $1.19 billion and advisory revenues reaching $634.2 million, the second-best quarter on record. The stock now trades well below its 52-week high of $70.00 and below its book value of $51.26 per share.

Talkspace shares are trading at $5.12, up 41.05% year-to-date as the acquisition premium has been priced in. The company had been executing well ahead of the deal: Q4 2025 revenue of $63.0 million grew 29.3% year-over-year, and the company ended the year debt-free with approximately $93 million in cash and securities.

Why the Move Matters Now

For Novo Nordisk, TD Cowen’s downgrade matters because the $42 target offers only modest upside from the current price of $39.78, and the analyst community is broadly recalibrating. The consensus target across all analysts sits at $48.79, but the direction of revisions has been consistently downward since the CagriSema data landed. The company’s forward P/E of 10x is low by historical standards, but the 2026 revenue guidance decline makes it difficult to anchor a recovery thesis without a new pipeline catalyst or meaningful M&A.

For Korn Ferry, the Truist target cut is a valuation call in an environment where staffing and consulting multiples have compressed. With the stock trading at roughly 12x trailing earnings and a consensus target of $79, the Buy rating from Truist still implies meaningful upside — the target reduction just reflects where sector multiples sit today, not a deterioration in the business.

Morgan Stanley’s pre-earnings adjustment on Jefferies reflects the firm’s view that advisory activity will be the soft spot in an otherwise reasonable quarter. With the stock trading at a significant discount to book value and Goldman’s revised $61 target still implying substantial upside from $38.16, the Buy rating signals confidence in a recovery — but the legal overhang from First Brands-related litigation adds a layer of uncertainty that the target alone cannot fully capture.

The Talkspace acquisition at $5.25 per share represents a straightforward outcome for investors. The deal was unanimously approved by both boards and is expected to close in Q3 2026, subject to shareholder and regulatory approvals. The $13 cents of spread between the current price and the deal price is the only return left on the table for holders.

What Analysts Are Watching

Novo Nordisk’s situation is one where the fundamentals of the business — strong obesity drug sales, a new share repurchase program, and a dividend yield of 4.67% — remain intact, but the pipeline setback with CagriSema has materially shifted the competitive outlook. Analysts watching the stock are focused on whether the oral Wegovy launch and pipeline depth can offset the loss of CagriSema’s expected contribution, rather than extrapolating the recent price decline in either direction.

Korn Ferry’s dividend increase to $0.55 per quarter — the sixth consecutive annual increase — and a record backlog of $1.85 billion suggest management confidence in the durability of the business. Korn Ferry’s growing dividend and analyst Buy consensus reflect the current state of analyst sentiment, even with the target reduction.

Jefferies’ deep discount to book value and analyst targets reflects a stock where legal uncertainty is doing most of the work in depressing sentiment. Jefferies trades at a significant discount to both book value and analyst price targets, with legal uncertainty from the First Brands-related litigation and regulatory inquiries adding a layer of risk that could take time to resolve.

With the deal announced, attention turns to the mechanics of the close. The acquisition removes both the upside and the downside from here.

Key Risks to Watch

• Novo Nordisk pipeline risk: With CagriSema underperforming Eli Lilly’s tirzepatide, the competitive gap in next-generation obesity drugs has widened. A study finding that generic semaglutide could cost less than $3 per month adds a longer-term pricing threat to the core Ozempic and Wegovy franchises, and the 2026 sales guidance already reflects a projected revenue decline.
• Jefferies legal exposure: Multiple law firms are investigating potential securities law violations tied to the First Brands collapse, and Western Alliance filed a lawsuit over a $126.4 million soured loan linked to the same situation. The outcome and timeline of these proceedings remain uncertain and could continue to weigh on the stock regardless of operating performance.
• Korn Ferry macro sensitivity: With a beta of 1.33, Korn Ferry is more volatile than the broader market. Consulting and executive search spending tends to slow in economic downturns, and concerns around tariffs and macro uncertainty could dampen hiring activity in the segments where Korn Ferry has seen the strongest recent growth.

This is not personalized financial advice. 247wallst.com and its writers do not own the stocks mentioned. Always do your own due diligence before investing.